Destiny Pharma Notice to Register for 2021 AGM

Link to Full Article Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and […]

Destiny Pharma – Posting of Annual Report and Notice of AGM

Link to Full Article Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 4 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that the following documents are now available on the Company’s website at www.destinypharma.com […]

Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel

Link to Full Article Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001) Excellent safety profile. No treatment related adverse events Brighton, United Kingdom – 29th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel […]

Destiny Pharma Notice of Full Year Results and Clinical Trial Update

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Full Year Results and Clinical Trial Update Brighton, United Kingdom – 16th March 2021 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its financial results for […]

Destiny Pharma Announces Agreement with NIAID

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Agreement with NIAID to Evaluate a Novel XF-73 Formulation in Skin Wound Infection Brighton, United Kingdom, 15 March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces […]

Destiny Pharma CSO Joins UKRI COVID-19 Taskforce

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Chief Scientific Officer Dr Bill Love Joins UKRI COVID-19 Research and Innovation Taskforce Brighton, United Kingdom – 10th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can […]

Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Brazilian Patent Granted for XF-73 nasal gel preventing post-surgical infections Brighton, United Kingdom – 3rd February 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening […]

Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma plc strengthens its Scientific Advisory Board with the appointment of Professor Mark Wilcox A recognised leader in UK/NHS infection prevention and control, and a renowned expert in C. difficile infection Brighton, United Kingdom – 2 February 2021 – Destiny Pharma Plc (AIM: […]

Destiny Pharma Phase 2b trial of XF-73 completes recruitment

Link to Full Article Phase 2b clinical trial of XF-73 completes patient recruitment   Results expected in Q1 2021 Brighton, United Kingdom – 5th January 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that its XF-73 […]

Destiny Pharma Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections

Link to Full Article Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the […]